Anti-oncogene Ribozymes for Cancer Gene Therapy

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 207-257

  Irie, Akira ^a,b   Kijima, Hiroshi ^a   Ohkawa, Tsukasa ^a,b   Bouffard, David Y ^a,b   Suzuki, Toshiya ^a,b   Curcio, Lisa D ^a   Holm, Per Sonne ^a   Sassani, Alex ^a   Scanlon, Kevin J ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME; RNA;

ANIMAL; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETICS; HUMAN; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; ONCOGENE; REVIEW;

ANIMALS; BASE SEQUENCE; GENE THERAPY; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOGENES; RNA; RNA, CATALYTIC;

EID: 0030623769     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60141-6     Document Type: Article

References (326)

1. Acsadi G., Dickson G., Love D.R., Jani A., Walsh F.S., Gurusignhe A., Wolff J.A., and Davies K.E. Human dystrophin expression in mdx mice after intracellular injection of DNA constructs. Nature (London) 352 (1991) 815-818
2. Acsadi G., Jiao S., Jani A., Duke D., Williams P., Chong W., and Wolf J.A. Direct gene transfer and expression into heart in vivo. New Biol. 3 (1991) 71-81
3. Addison C., Braciak T., Ralston R., Muller W.J., Gauldie J., and Graham F.L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8522-8526
4. Albino A.P. The role of oncogenes and growth factors in progressive melanomagenesis. Pigm. Cell Res. 2 (1992) 199-218
5. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (Cambridge, Mass.) 53 (1988) 549-554
6. Anderson P., Monforte J., Tritz R., Nesbitt S., Hearst J., and Hampel A. Mutagenesis of the hairpin ribozyme. Nucleic Acids Res. 22 (1994) 1096-1100
7. Anderson W.F., Blaese R.M., and Culver K. The ADA human gene therapy clinical protocol. Hum. Gene Ther. 1 (1990) 331-362
8. Aoki K., Yoshida T., Sugimura T., and Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 55 (1995) 3810-3816
9. Ball N.J., Yohn J.J., Morelli J.G., Norris D.A., Golitz L.E., and Hoeffler J.P. Ras mutations in human melanoma: A marker of malignant progression. J. Invest. Dermatol. 102 (1994) 285-290
10. Barbacid M. ras genes. Annu. Rev. Biochem. 56 (1987) 779-827
11. Bartlett J.S., Quattrocchi K.B., and Samulski R.J. The development of adeno-associated virus as a vector for cancer gene therapy. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 27-39
12. Becker T.C., Noel R.J., Coats W.S., Gomez-Foix A.M., Alam T., Gerard R.D., and Newgard C.B. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43 (1994) 161-189
13. Beigelman L., McSwiggen J.A., Draper K.G., Gonzalez C., Jensen K., Karpeisky A.M., Modak A.S., Matulic-Adamic J., DiRenzo A.B., Haeberli P., Sweedler D., Tracz D., Grimm S., Wincott F.E., Thackray V.G., and Usman N. Chemical modification of hammerhead ribozyme. J. Biol. Chem. 270 (1995) 25702-25708
14. Bennett M.J., and Cullimore J.V. Selective cleavage of closely-related mRNAs by synthetic ribozymes. Nucleic Acids Res. 20 (1992) 831-837
15. Berinstein N., Matthay K.K., Papaphadjopoulos D., Levy R., and Sikic B.I. Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization of growth inhibition. Cancer Res. 47 (1987) 5954-5959
16. Berkner K.L., Schaffhausen B.S., Roberts T.M., and Sharp P.A. Abundant expression of polyomarvirus middle T antigen and dihydrofolate reductase in an adenovirus recombinant. J. Virol. 61 (1987) 1213-1220
17. Berns K.I. Parvoviridae and their replication. In: Fields B.M., and Knipe D.M. (Eds). Virology (1990), Raven Press, New York 1743-1759
18. Berns K.I., Cheung A., Ostrove J., and Lewis M. Adeno-associated virus latent infection. In: Mahy B.W.J., Minson A.C., and Darby G.K. (Eds). Virus Persistence (1982), Cambridge University Press, Cambridge, UK. 248
19. Bertino J.R. Karnofsky Memorial Lecture. Ode to methotrexate. J. Clin. Oncol. 11 (1993) 5-14
20. Bertling W.M., Garis M., Paspaleeva V., Zimmer A., Kreuter J., Nurnberg E., and Harrer P. Use of liposomes, viral capsids, and nanoparticles as DNA carriers. Biotechnol. Appl. Biochem. 13 (1991) 390-405
21. Bertram J., Palfner K., Killian M., Brysch W., Schlingensiepen K., Hiddemann W., and Kneba M. Reversal of multidrug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anti-Cancer Drugs 6 (1995) 124-134
22. Bertrand E., and Rossi J.J. Facilitation of hammerhead ribozymes catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J. 13 (1994) 2904-2912
23. Bertrand E., Pictet R., and Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function?. Nucleic Acids Res. 22 (1994) 293-300
24. Berzal-Herranz A., Joseph S., Chowrira B.M., Butcher S.E., and Burke J.M. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J. 12 (1993) 2564-2567
25. Bett A.J., Prevec L., and Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67 (1993) 5911-5921
26. Bishop J.M. Molecular themes in oncogenesis. Cell (Cambridge, Mass.) 64 (1991) 235-248
27. Blaese R.M. Development of gene therapy for immunodeficiency: Adenosine deaminase deficiency. Pediatr. Res. 33 (1993) 549-555
28. Blau H.M., and Springer M.L. Molecular medicine gene therapy-a novel form of drug delivery. N. Engl. J. Med. 333 (1995) 1204-1207
29. Boiziau C., Kufurst R., Cazenave C., Roig V., Thuong N.T., and Toulmé J.-J. Inhibition of translation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Res. 19 (1991) 1113-1119
30. Bos J.L. ras oncogenes in human cancer: A review. Cancer Res. 49 (1989) 4682-4689
31. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Ed A.J., and Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature (London) 27 (1987) 293-297
32. Branch A.D., and Robertson H.D. Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis δ agent. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10163-10167
33. Bratty J., Chartrand P., Ferbeyre G., and Cedergren R. The hammerhead RNA domain, a model ribozyme. Biochim. Biophys. Acta 1216 (1993) 345-359
34. Brody S.L., Jaffe H.A., Han S.K., Wersto R.P., and Crystal R.G. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum. Gene Ther. 5 (1994) 437-447
35. Brunton V.G., and Workman P. Cell-signaling targets for antitumor drug development. Cancer Chemother. Pharmacol. 32 (1993) 1-19
36. Butcher S.E., and Burke J.M. A photo-cross-linkable tertiary structure motif found in functionally distinct RNA molecules is essential for catalytic function of the hairpin ribozyme. Biochemistry 33 (1994) 992-999
37. Buzayan J.M., Hampel A., and Bruening G. Nucleotide sequence and newly formed phosphodiester bond of spontaneously limaged satellite tobacco ringspot virus RNA. Nucleic Acids Res. 14 (1986) 9729-9743
38. Buzayan J.M., Feldstein P.A., Bruening G., and Eckstein F. RNA mediated formation of a phosphorothioate diester bond. Biochem. Biophys. Res. Commun. 156 (1988) 340-347
39. Cameron F.H., and Jennings P.A. Specific gene suppression by engineered ribozymes in monkey cells. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 9139-9143
40. Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., and Soltoff S. Oncogenes and signal transduction. Cell (Cambridge, Mass.) 64 (1991) 281-302
41. Carter B.J. The growth cycle of adeno-associated virus. In: Tjissen P. (Ed). "Handbook of Parvoviruses" 1 (1990), CRC Press, Boca Raton, Florida. 155-168
42. Carter B.J., Mendelson E., and Trempe J.P. AAV DNA replication, integration, and genetics. In: Tjissen P. (Ed). Handbook of Parvoviruses 1 (1990), CRC Press, Boca Raton, Florida. 169-262
43. Castanotto D., Rossi J.J., and Sarver N. Antisense catalytic RNAs as therapeutic agents. Adv. Pharmacol. 25 (1994) 289-317
44. Cech T.R. Ribozymes and their medical implications. JAMA, J. Am. Med. Assoc. 260 (1988) 3030-3034
45. Cech T.R., and Uhlenbeck O.C. Hammerhead nailed down. Nature (London) 372 (1994) 39-40
46. Cech T.R., Zaug A.J., and Grabowski P.J. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell (Cambridge, Mass.) 27 (1981) 487-496
47. Cepko C.L., Roberts B.E., and Mulligan R.C. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell (Cambridge, Mass.) 37 (1984) 1053-1062
48. Chartrand P., Harvey S.C., Febeyre G., Usman N., and Cedergren R. An oligonucleotide that supports catalytic activity in the hammerhead ribozyme domain. Nucleic Acids Res. 23 (1995) 4091-4096
49. Chen C.-J., Banerjea A.C.A., Harmision G.G., Haglund K., and Schubert M. Multitarget-ribozymes directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20 (1992) 4581-4589
50. Chen P.-J., Kalpana G., Goldberg J., Mason W., Werner B., Gerin J., and Taylor J. Structure and replication of the genome of the hepatitis δ virus. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8774-8778
51. Chen S.-H., Shine H.D., Goodman J.C., Grossman R.G., and Woo S.L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3054-3057
52. Chen S.-H., Chen X.H., Wang Y., Kosai K., Fingegold M.J., Rich S.S., and Woo S.L. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2577-2581
53. Chowrira B.M., Berzal-Herranz A., and Burke J.M. Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature (London) 354 (1991) 320-322
54. Chowrira B.M., Berzal-Herranz A., Keller C.F., and Burke J.M. Four ribose 2-hydroxyl groups essential for catalytic function of the hairpin ribozyme. J. Biol. Chem. 268 (1993) 19458-19462
55. Christoffersen R.E., and Marr J.J. Ribozymes as human therapeutic agents. J. Med. Chem. 38 (1995) 2023-2037
56. Chroboczek J., Bieber F., and Jacrot B. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186 (1992) 280-285
57. Clayman G.L., el-Naggar A.K., Roth J.A., Zhang W.W., Goepfert H., Taylor D.L., and Liv T.J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55 (1995) 1-6
58. Coffin J.M. Retroviridae and their replication. In: Field B.N., Knipe D.M., Chanock R.M., Melnick J.L., Hirsch M.S., Monath T.P., and Roizman B. (Eds). Virology (1990), Raven Press, New York 1437-1489
59. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., and Deeley R.G. Overexpression of a transporter gene in multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
60. Cooney E.L., McElrath M.J., Corey L., Hu S.L., Collier A.C., Arolittia D., Hoffman M., Coombs R.W., Smith G.E., and Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1882-1886
61. Corrias M.V., and Tonini G.P. An oligomer complementary to the 5 end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 12 (1992) 1431-1438
62. Cotten M., Wagner E., Zatloukal K., Phillips S., Curiel D.T., and Birnstiel M.L. High-efficiency receptor-mediated delivery of small and large 48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6094-6098
63. Cristiano R.J., Smith L.C., and Woo S.L. Hepatic gene therapy: Adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 2122-2126
64. Curiel D.T., Agarwal S., Wagner E., and Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 8850-8854
65. Curiel D.T., Agarwal S., Romer M.U., Wagner E., Cotten M., Birnstiel M.L., and Boucher R.C. Gene transfer to respirator epithelial cells via the receptor-mediated endocytosis pathway. Am. J. Respir. Cell Mol. Biol. 6 (1992) 247-252
66. Curiel D.T., Wagner E., Cotten M., Birnstiel M.L., Agarwal S., Li C.M., Loechel S., and Hu P.C. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum. Gene Ther. 3 (1992) 147-154
67. Czubayko F., Riegel A.T., and Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J. Biol. Chem. 269 (1994) 21358-21363
68. Dai Y., Roman M., Naviaux R.K., and Verma I.M. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10892-10895
69. Danos O., and Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6460-6464
70. DeCaprio J.A., Ludlow J.W., Figge J., Stein J.Y., Huang C.M., Lee W.H., Marsilio E., Paucha E., and Livingstone D.M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (Cambridge, Mass.) 54 (1988) 275-283
71. de la Maza L.M., and Carter B.J. Molecular structure of adeno-associated virus variant DNA. J. Biol. Chem. 255 (1980) 3194-3203
72. DeLuca N.A., McCarthy A.M., and Schaffer P.A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate early regulatory protein ICP4. J. Virol. 56 (1985) 558-570
73. Dorai T., Kobayashi H., Holland J.F., and Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol. Pharmacol. 46 (1994) 437-444
74. Dougherty J.P., Wisnewski R., Yang S., Yang S.L., Rhoode B.W., and Termin H.M. New retrovirus helper cells with almost no nucleotide homology to retrovirus vectors. J. Virol. 63 (1989) 3209-3212
75. Efferth T., and Volm M. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50 (1993) 303-308
76. Efstathiou S., and Minson A.C. Herpes virus based vectors. Br. Med. Bull. 51 (1995) 45-55
77. Egan S.E., and Weinberg R.A. The pathway to signal achievement. Nature (London) 365 (1993) 781-783
78. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 131-171
79. Engelhardt J.F., Ye X., Doranz B., and Wilson J.M. Ablation of E2A in recombinant adenovirus improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6196-6200
80. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell (Cambridge, Mass.) 61 (1990) 759-767
81. Fedor M.J., and Uhlenbeck O.C. Substrate sequence effects on "hammerhead" RNA catalytic efficiency. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 1668-1672
82. Feldstein P.A., and Bruening G. Catalytically active geometry in the reversible circularization of "mini-monomer" RNAs derived from the complementary strand of tobacco ringspot virus satellite RNA. Nucleic Acids Res. 21 (1993) 1991-1998
83. Feldstein P.A., Buzayan J.M., and Bruening G. Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA. Gene 82 (1989) 53-61
84. Felgner J.H., Kumar R., Sridhar C.M., Wheeler C.J., Tsai Y.J., Border R., Ramsey P., Martin M., and Felgner P.L. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269 (1994) 2550-2561
85. Felgner P.L., and Ringold G.M. Cationic liposome-mediated transfection. Nature (London) 337 (1989) 387-388
86. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., and Ringold G.M. Lipofection: A highly efficient lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7413-7417
87. Feng M., Cabrera G., Deshane J., Scanlon K.J., and Curiel D.T. Neoplastic reversion accomplished by high efficiency adenoviral mediated delivery of anti-ras ribozymes. Cancer Res. 55 (1995) 2024-2028
88. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 265-269
89. Ford J.M., and Hait W.N. Pharmacologic circumvention of multidrug resistance. Cytotechnology 12 (1993) 171-212
90. Forrester K., Almoguera C., Han K., Grizzle W.E., and Perucho M. Detection of high incidence of K-ras oncogenes during human tumorigenesis. Nature (London) 327 (1987) 298-303
91. Forster A.C., and Symons R.H. Self-cleavage of plus and minus RNAs of a virusoid and structural model for the active sites. Cell (Cambridge, Mass.) 49 (1987) 211-220
92. Foulds L. The natural history of cancer. J. Chronic Dis. 8 (1958) 2-37
93. Funato T., Yoshida E., Jiao L., Tone T., Kashani-Sabet M., and Scanlon K.J. The utility of the anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv. Enzyme Regul. 32 (1992) 195-209
94. Funato T., Shitara T., Tone T., Jiao L., Kashani-Sabet M., and Scanlon K.J. Suppression of H-ras-mediated transformation in NIH 3T3 cells by a ras ribozyme. Biochem. Pharmacol. 48 (1994) 1471-1475
95. Garte S.J. The c-myc oncogene in tumor progression. Crit. Rev. Oncog. 4 (1993) 435-449
96. Geller A.I., and Federoff H.J. The use of HSV-1 vectors to introduce heterologous genes into neurons: Implications for gene therapy. In: Cohen-Hauguenauer O., and Borion M. (Eds). Human Gene Transfer (1991), John Libbey Eurotext, France. 63-73
97. Geller A.I., Keyomarsi K., Bryan J., and Pardee A.B. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physicology. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8950-8954
98. Gerlach W.L., Llewellyn D., and Haseloff J. Construction of a plant disease resistance gene from the satellite RNA of tobacco ringspot virus. Nature (London) 328 (1987) 802-805
99. Gewirtz A.M. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant. 14 Suppl. 3 (1994) 57-61
100. Glorioso J.G., Goins W.F., and Fink D.J. Herpes simplex virus-based vectors. Semin. Virol. 3 (1992) 265-276
101. Goebel S.J., Johnson G.P., Perkus M.E., Davis S.W., Winslow J.P., and Paoletti E. The complete DNA sequence of vaccinia virus. Virology 179 (1990) 247-266
102. Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2-O-methylation. Nucleic Acids Res. 20 (1992) 4607-4612
103. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
104. Gottschalk S., Cristiano R.J., Smith L.C., and Woo S.L.C. Folate receptor mediated DNA delivery into tumor cells: Potosomal disruption results in enhanced gene expression. Gene Ther. 1 (1993) 185-191
105. Graham B.S., Matthews T.J., Belshe R.B., Clements M.L., Dolin R., Wright P.F., Gorse G.J., Schwarts D.H., Keefer M.C., and Bologhesi D.P. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167 (1993) 533-537
106. Graham F.L., Smiley J., Russel W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J. Gen. Virol. 36 (1977) 59-74
107. Gros P., Croop J., Roninson I., Varshavsky A., and Housman D.E. Isolation and characterization of DNA sequences amplified in multidrug resistant hamster cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 337-341
108. Grossman Z., Mendelson E., Brok-Simoni F., Milegvir F., Leifner Y., Rechavi G., and Ramot B. Detection of adeno-associated virus type 2 in human peripheral blood cells. J. Gen. Virol. 73 (1992) 961-966
109. Grunewald K., Lyons J., Frohlich A., Feichtinger H., Weger R.A., Schwab G., Janssen J.W., and Bartram C.R. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer 43 (1989) 1037-1041
110. Guerrier-Takada C., Gardiner K., Marsh T., Pace N., and Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (Cambridge, Mass.) 35 (1983) 849-857
111. Gunning P., Leavitt J., Muscat G., Ng S., and Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 4831-4835
112. Hampel A., and Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 28 (1989) 4929-4933
113. Hampel A., Tritz R., Hicks M., and Cruz P. "Hairpin" catalytic RNA model: Evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res. 18 (1990) 299-304
114. Harris C.E., Agarwal S., Hu P., Wagner E., and Curiel D.T. Receptor-mediated gene transfer to airway epithelial cells in primary culture. Am. J. Respir. Cell Mol. Biol. 9 (1993) 441-447
115. Haseloff J., and Gerlach W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (London) 334 (1988) 585-591
116. Haseloff J., and Gerlach W.L. Sequences required for self-catalyzed cleavage of the satellite RNA of tobacco ringspot virus. Gene 82 (1989) 43-52
117. He Y.-K., Lu C.D., and Qi G. In vitro cleavage of HPV16 E6 and E7 RNA fragments by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids. FEBS Lett. 322 (1993) 21-24
118. Hearst J.E. A photochemical investigation of the dynamics of oligonucleotide hybridization. Annu. Rev. Phys. Chem. 39 (1988) 291-315
119. Heidenreich O., and Eckstein F. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J. Biol. Chem. 267 (1992) 1904-1909
120. Heidenreich O., Pieken W., and Eckstein F. Chemically modified RNA: Approaches and applications. FASEB J. 7 (1993) 90-96
121. Heidenreich O., Benseler F., Fahrenholz A., and Eckstein F. High activity and stability of hammerhead ribozymes containing 2-modified pyrimidine nucleosides and phosphorothioates. J. Biol. Chem. 269 (1994) 2131-2138
122. Hendry P., and McCall M.J. A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes. Nucleic Acids Res. 23 (1995) 3928-3936
123. Hendry P., McCall M.J., Santiago F.S., and Jennings P.A. A ribozyme with DNA in the hybridizing arms displays enhanced cleavage ability. Nucleic Acids Res. 20 (1992) 5737-5741
124. Hendry P., McCall M.J., Santiago F.S., and Jennings P.A. In vitro activity of minimized hammerhead ribozyme. Nucleic Acids Res. 23 (1995) 3922-3927
125. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6921-6925
126. Herschlag D., Khosla M., Tsuchihashi Z., and Karpel R.L. An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis. EMBO J. 13 (1994) 2913-2914
127. Hertel K.J., Pardi A., Uhlenbeck O.C., Koizumi M., Ohtsuka E., Uesugi S., Cedergren R., Eckstein F., Gerlach W.L., Hodgson R., and Symons R.H. Numbering system for the hammerhead. Nucleic Acids Res. 20 (1992) 3252
128. Hock R.A., Miller A.D., and Osborne W.R.A. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 74 (1989) 876-881
129. Holm P.S., Scanlon K.J., and Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer 70 (1994) 239-243
130. Holm P.S., Dietel M., and Krupp G. Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene 167 (1995) 221-225
131. Homann M., Tzortzakaki S., Rittner K., Sczkiel G., and Tabler M. Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res. 21 (1993) 2809-2814
132. Hunter T. Cooperation between oncogenes. Cell (Cambridge, Mass.) 64 (1991) 249-270
133. Hutchins C.J., Rathjen P.D., Forster A.C., and Symons R.H. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 14 (1986) 3627-3640
134. Inouye M. Antisense RNA: Its functions and applications in gene regulation-a review. Gene 72 (1988) 25-34
135. Ishida H., Kijima H., Ohta Y., Kashani-Sabet M., and Scanlon K.J. Mechanisms of cisplatin resistance and its reversal in human tumors. In: Kallen J.A. (Ed). Alternative Mechanisms of Multidrug Resistance in Cancer (1995), Birkhaeuser, Boston. 225-264
136. Jaeger J.A., Turner D.H., and Zuker M. Improved predictions of secondary structures for RNA. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7706-7710
137. Jaroszweski J.W., Kaplan O., Syi J., Sehested M., Faustino P.J., and Cohen J.S. Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun. 2 (1990) 287-294
138. Johnson P.A., Miyanohara A., Levin F., Cahill T., and Friedman T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J. Virol. 66 (1992) 2952-2965
139. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1 (1994) 51-64
140. Joseph S., Berzal-Herranz A., Chowrira B.M., Butcher S.E., and Burke J.M. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates. Genes Dev. 7 (1993) 130-138
141. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
142. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221 (1983) 1285-1288
143. Kartner N., Evernden-Porelle D., Bradley G., and Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature (London) 316 (1985) 820-823
144. Kashani-Sabet M., and Scanlon K.J. Application of ribozymes to cancer gene therapy. Cancer Gene Ther. 2 (1995) 213-223
145. Kashani-Sabet M., Funato T., Tone T., Jiao L., Wang W., Yoshida E., Kashfian B.I., Shitara T., Wu A.M., Moreno J.G., Traweek S.T., Ahlering T.E., and Scanlon K.J. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 2 (1992) 3-15
146. Kashani-Sabet M., Funato T., Florenes V.A., Fodstad O., and Scanlon K.J. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54 (1994) 900-902
147. Kennedy P.G.E., and Steiner I. The use of herpes simplex virus vectors for gene therapy in neurological diseases. Q. J. Med. 86 (1993) 697-702
148. Kiehntopf M., Brach M.A., Licht T., Petschauer S., Karawajew L., Kirschning C., and Hermann F. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 13 (1994) 4645-4652
149. Kiehntopf M., Esquivel E.L., Brach M.A., and Herrmann F. Clinical applications of ribozymes. Lancet 345 (1995) 1027-1031
150. Kiehntopf M., Esquivel E.L., Brach M.A., and Herrmann F. Ribozymes: Biology, biochemistry, and implications for clinical medicine. J. Mol. Med. 73 (1995) 65-71
151. Kijima H., Ishida H., Ohkawa T., Kashani-Sabet M., and Scanlon K.J. Therapeutic application of ribozymes. Pharmacol. Ther. 68 (1995) 247-267
152. Kijima H., Bouffard D.Y., and Scanlon K.J. Ribozyme-mediated reversal of human pancreatic carcinoma phenotype. In: Ikehara S. (Ed). "Proceedings of International Symposium on Bone Marrow Transplantation" (1996), Springer, Berlin 153-163
153. Kobayashi H., Kim N., Halatsch M., and Ohnuma T. Specificity of ribozyme designed for mutated DHFR mRNA. Biochem. Pharmacol. 47 (1993) 1607-1613
154. Kobayashi H., Dorai T., Holland J.F., and Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by MDR-1(PGY-1) ribozyme. Cancer Res. 54 (1994) 1271-1275
155. Koizumi M., Hayase Y., Iwai S., Kamiya H., Inoue H., and Ohtsuka E. Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. 17 (1989) 7059-7071
156. Koizumi M., Kamiya H., and Ohtsuka E. Ribozymes designed to inhibit transformation of NIH 3T3 cells by the activated c-Ha-ras gene. Gene 117 (1992) 179-184
157. Kotin R.M., Siniscalco M., Samulski R.J., Zhu X.D., Hunter L., Laughlin C.A., McLaughlin S., Muzyczka N., Rocchi M., and Berns K.I. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2211-2215
158. Kotin R.M., Linden R.M., and Berns K.I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by nonhomologous recombination. EMBO J. 11 (1992) 5071-5078
159. Kozarsky K.F., and Wilson J.M. Gene therapy adenvirus vectors. Curr. Opin. Genet. Dev. 3 (1993) 499-503
160. Krishnamachary N., and Center M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53 (1993) 3658-3661
161. Kruger K., Grabowski P.J., Zaug A.J., Sands J., Gottschling D.E., and Cech T.R. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell (Cambridge, Mass.) 31 (1982) 147-157
162. Kumar P.K.R., and Ellington A.D. Artifical evolution and natural ribozymes. FASEB J. 9 (1995) 1183-1195
163. Kumar P.K.R., Taira K., and Nishikawa S. Chemical probing studies of variants of the genomic hepatitis delta virus ribozyme by primer extension analysis. Biochemistry 33 (1994) 583-592
164. Kurzock R., Gutterman J.U., and Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319 (1988) 990-998
165. Laface D., Hermonat P., Wakeland E., and Peck A. Gene transfer into hematopoietic progenitor cells mediated by an adeno-associated virus vector. Virology 162 (1988) 483-486
166. Lange W., Canten E.M., Finke J., and Dolken G. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7 (1993) 1786-1794
167. Lange W., Daskalakis M., Finke J., and Dolken G. Comparision of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett. 338 (1994) 175-178
168. Larsson S., Hotchkiss G., Andang M., Nyholm T., Inzunza J., Jansoon I., and Ahrlund-Richter L. Reduced β-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 22 (1994) 2242-2248
169. Lechner M.S., Mack D.H., Finicle A.B., Crook T., Vousden K.H., and Laimins L.A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11 (1992) 3045-3052
170. Legendre J.Y., and Szoka F.C. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic lipsomes. Pharmacol. Res. 9 (1992) 1235-1242
171. Leopold L.H., Shore S.K., Newkirk T.A., Reddy R.M.V., and Reddy E.P. Multi-unit ribozyme mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85 (1995) 2162-2170
172. Leserman L.D., Weinstein J.N., Bluraenthal R., and Terry W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 4089-4093
173. Lichtenberg D. Liposomes: Preparation, characterization, and preservation. Methods Biochem. Anal. 33 (1988) 337-468
174. Linnenbach A.J., Huebner K., Reddy P., Herlyn M., Parmiter A.H., Nowell P.C., and Koprowski H. Structural alteration in the MYB proto-oncogene and deletion within the gene encoding α-type protein kinase C in human melanoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 74-78
175. Litzinger D.C., and Huang L. Phosphatidylethanolamine liposomes: Drug delivery, gene transfer and immunodiagnostic applications. Biochim. Biophys. Acta 1113 (1992) 201-227
176. Liu T.J., Zhang W.W., Taylor D.L., Goephert H., and Clayman G.L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54 (1994) 2287-2291
177. Lowy D.R., Kirnbauer R., and Schiller J.T. Genital human papillomavirus infection. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2436-2440
178. Lu C.D., Chatterjee S., Brar D., and Wong Jr. K.K. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther. 1 (1994) 267-277
179. Maddoen C.S., Morrow C.S., Nakagawa M., Goldsmith M.E., Fairchild C.R., and Cowan K.H. Identification of the 5 and 3 sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J. Biol. Chem. 268 (1993) 8290-8297
180. Markowitz D., Goff S., and Bank A. Construction and used of a safe and efficient amphotropic packaging cell line. Virology 167 (1988) 400-406
181. Marquardt D., McCrone S., and Center M.S. Mechanisms of multidrug resistance in HL-60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res. 50 (1990) 1426-1430
182. Marschall P., Thomson J.B., and Eckstein F. Inhibition of gene expression with ribozymes. Cell. Mol. Neurobiol. 14 (1994) 523-538
183. Marsh W., Sicheri R., and Center M.S. Isolation and characterization of Adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res. 46 (1986) 4053-4057
184. Matsushita H., Kobayashi H., Mori S., Kizaki M., and Ikeda Y. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem. Biophys. Res. Commun. 215 (1995) 431-437
185. McCall M.J., Hendry P., and Jennings P.A. Minimal sequence requirements for ribozyme activity. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 5710-5714
186. McGrath T., and Center M.S. Adriamycin resistance in HL-60 cells in the absence of detectable P-glycoprotein. Biochem. Biophys. Res. Commun. 145 (1987) 1171-1176
187. McGrath T., Latoud C., Arnold S.T., Safa A.R., Felsted R.L., and Center M.S. Mechanisms of multidrug resistance in HL60 cells: Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 38 (1989) 3611-3619
188. McLaughlin S.K., Collis P., Hermonat P.L., and Muzyczk N. Adeno-associated virus general trasnduction vectors: Analysis of proviral structures. J. Virol. 62 (1988) 1963-1973
189. Melton D.A. Injected antisense RNAs specifically block messenger RNA translation in vivo. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 144-148
190. Mendelson E., Grossman Z., Mileguir F., Rechavi G., and Carter B.J. Replication of adeno-associated virus type 2 in human lymphocytic cells and interaction with HIV-1. Virology 187 (1992) 453-463
191. Milhuad P.G., Machy P., Lebleu B., and Leserman L. Antibody-targeted liposomes containing poly(rI)-poly(rC) exert a specific antiviral and toxic effect on cells primed with interferon alpha/beta or gamma. Biochim. Biophys. Acta 1135 (1989) 269-274
192. Miller A.D., Miller D.C., Garcia J.V., and Lynch C.M. Use of retroviral vectors for gene transfer and expression. In: Wu R. (Ed). Methods in Enzymology 217 (1993), Academic Press, San Diego, California. 581-599
193. Miller D. Progress toward human gene therapy. Blood 76 (1990) 271-599
194. Miller N., and Vile R. Targeted vectors for gene therapy. FASEB J. 9 (1995) 190-199
195. Mirski S.E.L., Gerlach J.H., and Cole S.P.C. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res. 47 (1987) 2594-2598
196. Monia B.P., Johnston J.F., Ecker D.J., Zounes M.A., Lima W.F., and Freier S.M. Selective inhibition of mutant Ha-ras messenger RNA expression by antisense oligonucleotides. J. Biol. Chem. 267 (1992) 19954-19962
197. Morgan R.A., and Anderson W.F. Human gene therapy. Annu. Rev. Biochem. 62 (1993) 191-217
198. Moss B. Herpes simplex viruses and their replication. In: Field B.N., Knipe D.M., Chanock R.M., Melnick J.L., Hirsch M.S., Monath T.P., and Roziman B. (Eds). Virology (1990), Raven Press, New York 2079-2099
199. Müller M., Meijer C., Zaman G.J.R., Borst P., Scheper R.J., Mulder N.H., de Vries E.G., and Jansen P.L.M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 13033-13037
200. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158 (1992) 97-129
201. Nabel E.G., Plautz G., Boyce F.M., Stanley J.C., and Nabel G.J. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244 (1989) 1342-1344
202. Nabel E.G., Plautz G., and Nabel G.J. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249 (1990) 1285-1288
203. Nabel G.J., Nabel E.G., Yang Z.-Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., and Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity and a lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11307-11311
204. Nahreini P., Woody M.J., Zhou S.Z., and Srivastava A. Versatile adeno-associated virus 2-based vectors for constructing recombinant virions. Gene 124 (1993) 257-262
205. Nakamaye K.L., and Eckstein F. AUA-cleaving hammerhead ribozymes: Attempted selection for improved cleavage. Biochemistry 33 (1994) 1271-1277
206. Nakashima E., Matsushita R., Negishi H., Nomura M., Harada S., Yamamoto H., Miyamoto K., and Ichimura F. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide. J. Pharm. Sci. 84 10 (1995) 1205
207. Ng M.M.P., Benseler F., Tuschl T., and Eckstein F. Isoguanosine substitution of conserved adenosines in the hammerhead ribozyme. Biochemistry 33 (1994) 12119-12126
208. Ohkawa J., Koguma T., Okhda T., and Taira K. Ribozyme: From mechanistic studies to applications in vivo. J. Biochem. (Tokyo) 118 (1995) 251-258
209. Ohkawa T., Kijima H., Irie A., Horng G., Kaminski A., Tsai J., Kashfian B.I., and Scanlon K.J. Oligonucleotide modulation of multidrug resistance gene expression. In: Gupta S., and Tsuruo T. (Eds). "Multidrug Resistance in Cancer Cells Cellular, Biochemical, Molecular and Biological Aspects" (1996), Wiley, London. 413-433
210. Ohnuma T., Lo R.J., Scanlon K.J., Kamen B.A., Ohnoshi T., Wolman S.R., and Holland J.F. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res. 45 (1985) 1815-1822
211. Ohta Y., Tone T., Shitara T., Funato T., Jiao L., Kashfian B.I., Yoshida E., Horng M., Tsai P., Lauterbach K., Kashani-Sabet M., Florenes V.A., Fodstad O.Y., and Scanlon K.J. H-ras ribozyme mediated alteration of the human melanoma phenotype. Ann. N. Y. Acad. Sci. 716 (1994) 242-253
212. Ohta Y., Kijima H., Kashani-Sabet M., and Scanlon K.J. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J. Invest. Dermatol. 106 (1996) 1-6
213. Ohta Y., Kijima H., Kashani-Sabet M., and Scanlon K.J. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res. 24 (1996) 938-942
214. Pachuk C.J., Yoon K., Moelling K., and Coney L.R. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to noncontiguous sequences. Nucleic Acids Res. 22 (1993) 301-307
215. Palfner K., Kneba M., Hiddenmann W., and Bertram J. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA. Biol. Chem. Hoppe-Seyler 376 (1995) 289-295
216. Palmer T.D., Miller A.D., Reeder R.H., and Mestay B. Efficient expression of a protein coding gene under the control of an RNA polymerase I promoter. Nucleic Acids Res. 21 (1993) 3451-3457
217. Paolella G., Sproat B.S., and Lamond A.L. Nuclease resistant ribozymes with high catalytic activity. EMBO J. 11 (1992) 1913-1919
218. Perez-Cruet M.J., Trask T.W., Chen S.H., Goodman J.C., Woo S.L., Grossman R.G., and Shine H.D. Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39 (1994) 506-511
219. Perreault J.-P., Wu T., Cousineau B., Ogilvie K.K., and Cedergren R. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature (London) 344 (1990) 565-567
220. Perreault J.-P., Labuda D., Usman N., Yang J.-H., and Cedergren R. Relationship between 2-hydroxyls and magnesium binding in the hammerhead RNA domain: A model for ribozyme catalysis. Biochemistry 30 (1991) 4020-4025
221. Perriman R., Delves A., and Gerlach W.L. Extended target-site specificity for a hammerhead ribozyme. Gene 113 (1992) 157-163
222. Perrotta A.T., and Been M.D. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis δ virus RNA sequence. Biochemistry 31 (1992) 16-21
223. Pieken W.A., Olsen D.B., Benseler F., Aurup H., and Eckstein F. Kinetic characterization of ribonuclease-resistant 2-modified hammerhead ribozymes. Science 253 (1991) 314-317
224. Plautz G.E., Wu B.-Y., Gao X., Huang L., and Nabel G.J. Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadal localization. Hum. Gene Ther. 3 (1992) 649-656
225. Plautz G.E., Yang Z., Wu B., Gao X., Huang L., and Nabel G.J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4645-4649
226. Pley H.W., Flaherty K.M., and McKay D.B. Three-dimensional structure of a hammerhead ribozyme. Nature (London) 372 (1994) 68-74
227. Ransone L.J., and Verma I.M. Nuclear proto-oncogenes Fos and Jun. Annu. Rev. Biol. 6 (1990) 539-557
228. Roberts T.M. A signal chain of events. Nature (London) 360 (1992) 534-535
229. Rodenhuis S., van de Wetering M.L., Mooi W.J., Evers S.G., Van Zandwij K.N., and Bos J.L. Mutational activation of the K-ras oncogene; a possible pathogenic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317 (1987) 929-935
230. Roe T.Y., Reynolds T.C., Yu G., and Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12 (1993) 2099-2108
231. Roizman B., and Sears A.E. Herpes simplex viruses and their replication. In: Field B.N., Knipe D.M., Chanock R.M., Melnick J.L., Hirsch M.S., Monath T.P., and Roizman B. (Eds). Virology (1990), Raven Press, New York 1795-1841
232. Roninson I.B. "Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells." (1991), Plenum, New York
233. Roninson I.B., Chin J.E., Choi K., Gros P., Housman D.E., Fojo A., Gottesman M.M., and Pastan I. Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 4538-4542
234. Roth J.A., Mukhopadhyay T., Zhang W.-W., Fujiwara T., and Georges R. Gene replacement strategies for the prevention and therapy of cancer. Eur. J. Cancer 30A (1994) 20032-20037
235. Roth J.A., Mukhopadhyay T., Zhang W., Fujiwara T., and Georges R. Gene replacement strategies for the prevention and therapy of cancer. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 229-233
236. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (London) 243 (1973) 290-293
237. Ruffner D.E., Stormo G.D., and Uhlenbeck O.C. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29 (1990) 10695-10702
238. Russell D.W. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects. Eur. J. Cancer 30A (1994) 1165-1171
239. Russell D.W., Miller A.D., and Alexander I.E. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8915-8919
240. Samulski R.J. Adeno-associated virus: integration at a specific chromosomal locus. Curr. Opin. Biotech. 3 (1993) 74-80
241. Samulski R.J., Chang L.-S., and Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63 (1989) 3822-3828
242. San H., Yang Z.-H., Pompili V.J., Jaffe M.L., Plautz G.E., Xu L., Feigner J.H., Wheeler C.J., Feigner P.L., Gao X., Huang L., Gordon D., Nabel G.J., and Nabel E.G. Safety and short-term toxicity of novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. 4 (1993) 781-788
243. Scanlon K.J., Jiao L., Funato T., Wang W., Tone T., Rossi J.J., and Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10591-10595
244. Scanlon K.J., Kashani-Sabet M., Tone T., and Funato T. Cisplatin resistance in human cancers. Pharmacol. Ther. 52 (1991) 385-406
245. Scanlon K.J., Ishida H., and Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11123-11127
246. Scanlon K.J., Ohta Y., Ishida H., Kijima H., Ohkawa T., Kaminski A., Tsai J., Horng G., and Kashani-Sabet M. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J. 9 (1995) 1288-1296
247. Scheffer G.L., Wijngaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J.L.M., Clevers H.C., and Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1 (1995) 578-582
248. Scheper R.J., Broxterman H.J., Scheffer G.L., Kaaijk P., Dalton W.S., van Heijningen T.H.M., van Kalken C.K., Slovak M.L., de Vries E.G.E., van der Valk P., Meijer C.J.L.M., and Pinedo H.M. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53 (1993) 1475-1479
249. Seemayer T.A., and Cavenee W.K. Biology of diseases: Molecular mechanisms of oncogenesis. Lab. Invest. 60 (1989) 585-599
250. Sen A., Dunnmon S.A., Gerard R.D., and Chien K.R. Terminally differentiated neonatal rat myocardial cells proliferate and maintain specific differentiated functions following expression of SV40 large T antigen. J. Biol. Chem. 263 (1988) 19132-19136
251. Seth P. Adenovirus-dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by penton base protein. J. Virol. 68 (1994) 1204-1206
252. Shi Y., Glynn J.M., Guilbert L.J., Cotter T.G., Bissonnette R.P., and Green D.R. Role of c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257 (1992) 212-214
253. Shimayama T., Wishikawa F., Nishidawa S., and Taira K. Nuclease-resistant chimeric ribozymes containing dexoyribonucleotides and phosphorothioate linkages. Nucleic Acids Res. 21 (1993) 2605-2611
254. Shore S.K., Nabriss P.M., and Reddy E.P. Ribozyme-mediated cleavage of the BCR/ABL oncogene transcript; in vitro cleavage of RNA and in vivo loss of P210 protein kinase activity. Oncogene 8 (1993) 3183-3188
255. Sioud M., and Drlica K. Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7303-7307
256. Sioud M., Natvig J.B., and Forre O. Preformed ribozyme destroys tumor necrosis factor mRNA in human cells. J. Mol. Biol. 223 (1992) 831-835
257. Smith G.L., and Moss B. Infectious poxvirus vectors have a capacity for at least 25,000 base pairs of foreign DNA. Gene 25 (1983) 21-28
258. Smythe W.R., Hwang H.C., Amin K.M., Elshami A.A., Eck S.L., Davidson B.L., Wilson J.M., Kaiser L.R., and Albelda S.M. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann. Surg. 222 (1995) 78-86
259. Snyder D.S., Wu Y., Wang J.L., Rossi J.J., Swiderski P., Kaplan B.E., and Forman S.J. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82 (1993) 600-605
260. Solnick D. Construction of an adenovirus-SV40 recombinant producing SV40 T-antigen from adenovirus late promoter. Cell (Cambridge, Mass.) 24 (1981) 135-143
261. Stamatatos L., Leventis R., Zuckermann M.J., and Silivius J.R. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. Biochemistry 17 (1988) 3917-3925
262. Stehelin D., Varmus H.E., Bishop J.M., and Vogt P.K. DNA related to the transforming gene(s) of avian sarcoma virus is present in normal avian DNA. Nature (London) 260 (1976) 170-173
263. Stein C.A., and Cheng Y.-C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical?. Science 261 (1993) 1165-1171
264. Stein C.A., and Krieg A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4 (1995) 67-69
265. Stewart M.J., Plautz G.E., Del Buono L., Yang Z.-Y., Xu L., Gao X., Huang L., Nabel E.G., and Nabel G.J. Gene transfer in vivo with DNA-liposomes complexes: Safety and acute toxicity in mice. Hum. Gene Ther. 3 (1992) 267-275
266. Stull R.A., and Szoka F.C.J. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12 (1995) 465-483
267. Sullenger B.A., and Cech T.R. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262 (1993) 1566-1569
268. Sullenger B.A., and Cech T.R. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature (London) 371 (1994) 619-622
269. Sullivan S.M. Development of ribozymes for gene therapy. J. Invest. Dermatol. 103 (1994) 85S-89S.
270. Symons R.H. Small catalytic RNAs. Annu. Rev. Biochem. 61 (1992) 641-671
271. Symons R.H. Ribozymes. Curr. Opin. Struct. Biol. 4 (1994) 322-330
272. Taylor J.M. Hepatitis delta virus: Cis and trans functions required for replication. Cell (Cambridge, Mass.) 61 (1990) 371-373
273. Taylor N.R., Kaplan B.E., Swiderski T., Li H., and Rossi J.J. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res. 20 (1992) 4559-4565
274. Teeter L.D., Eckersberg T., Tsai Y., and Kuo M.T. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ. 2 (1991) 429-437
275. Temin H.M. Retrovirus vectors: Promise and reality. Science 246 (1989) 983
276. Thill G., Vasseur M., and Tanner N.K. Structural and sequence elements required for the self-cleaving activity of the hepatitis delta virus ribozyme. Biochemistry 32 (1993) 4254-4262
277. Thummel C.R., Tjian R., and Grodzicker T. Expression of SV40 T antigen under control of adenovirus promoter. Cell (Cambridge, Mass.) 23 (1981) 825-836
278. Tidd D.M. Synthetic oligonucleotides as therapeutic agents. Br. J. Cancer 63 (1991) 6-8
279. Tone T., Kashani-Sabet M., Funato T., Shitara T., Yoshida E., Kashfian B.I., Horng M., Fodstad O., and Scanlon K.J. Suppression of EJ cells tumorigenicity. In Vivo 7 (1993) 471-476
280. Trapnell B.C., and Gorziglia M. Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. 5 (1994) 617-625
281. Tratschin J.-D., Miller I.L., and Smith M.G. Adeno-associated virus vector for high-frequency intergration, expression, and rescue of genes in mammalian cells. Mol. Cell. Biol. 5 (1985) 3251-3260
282. Tritton T.R., and Hickman J.A. How to kill cancer cells: Membranes and cell signaling as targets in cancer chemotherapy. Cancer Cells 2 (1990) 95-105
283. Tsuchihashi Z., Khosla M., and Herschlag D. Protein enhancement of hammerhead ribozymes catalysis. Science 262 (1993) 99-102
284. Tuschl T., and Eckstein F. Hammerhead ribozymes: Importance of stem-loop II for activity. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 6991-6994
285. Tuschl T., Gohlke C., Jovin T.M., Westhof E., and Eckstein F. A three-dimensional model for the hammerhead ribozyme based on fluorescence measurements. Science 266 (1994) 785-788
286. Ueda K., Cardarelli C., Gottesman M.M., and Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 3004-3008
287. Ueda K., Clark D.P., Chen C.-J., Roninson I.B., Gottesman M.M., and Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262 (1987) 505-508
288. Ueda K., Pastan I., and Gottesman M.M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 262 (1987) 17432-17436
289. Uhlenbeck O.C. A small catalytic oligoribonucleotide. Nature (London) 328 (1987) 596-600
290. van Beusechem V.M., Kukler A., Heidt P.J., and Valerio D. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone marrow cells. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7640-7644
291. van Doren K., Hanahan D., and Gluzman Y. Infection of eukaryotic cells by helper-independent recombinant adenoviruses: Early region I is not obligatory for integration of viral DNA. J. Virol. 50 (1984) 606-614
292. van Tol H., Buzayan J.M., Feldstein P.A., Eckstein F., and Bruening G. Two autolytic processing reactions of a satellite RNA proceed with inversion of configuration. Nucleic Acids Res. 18 (1990) 1971-1975
293. Vasanthakumar G., and Ahmed N.K. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methyl phosphonates. Cancer Commun. 1 (1989) 225-232
294. Versnel M.A., Hagemeijer A., Bouts M.J., van der Kwast T.H., and Hoogesteden H.C. Expression of c-sis (PDGF-B chain) and PDGF-A chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 2 (1988) 601-605
295. Versnel M.A., Claesson-Welsh L., Hammacher A., Bouts M.J., van der Kwast T.H., Eriksson A., Willemsen R., Weima S.M., Hoogesteden H.C., Hagemeijer A., and Heldin C.-H. Human malignant mesothelioma cell lines express PDGF-beta receptors whereas cultured normal mesothelioma cells express predominately PDGF-alpha receptors. Oncogene 6 (1991) 2005-2011
296. Vile R.G., and Hart I.G. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53 (1993) 962-967
297. Wagner E., Zenke M., Cotten M., Beug H., and Birnstiel M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3410-3414
298. Wagner E., Plank C., Zatloukal K., Cotten M., and Birnstiel M.L. Influenza virus hemagglutinin HA-2N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene transfer vehicle. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7934-7938
299. Walz C., and Schlehofer J.R. Modification of some biological properties of HeLa cells containing adeno-associated virus DNA integrated into chromosome 17. J. Virol. 66 (1992) 2990-3002
300. Wang K.-S., Choo Q.-L., Weiner A.J., Ou J.-H., Najarian R.C., Thayer R.M., Mullenbach G.T., Denniston K.J., Gerin J.L., and Houghton M. Structure, sequence and expression of the hepatitis delta (δ) viral genome. Nature (London) 323 (1986) 508-514 corrigendum, 328: 456.
301. Wei C.-M., Gibson M., Spears P.G., and Scolnik E.M. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol. 39 (1981) 935-944
302. Weinberg R.A. Oncogenes, anti-oncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res. 49 (1989) 3713-3721
303. Weinberg R.A. Tumor suppressor genes. Science 254 (1992) 1138-1145
304. Weir J.P., and Narayanan P.R. The use of beta galactosidase as a marker gene to define the regulatory sequences of the herpes simplex virus type 1 glycoprotein C in recombinant herpes virus. Nucleic Acids Res. 16 (1988) 10267-10282
305. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus type 16 and 18 E6 protein with pS3. Science 248 (1990) 76-79
306. Whyte D., Buchkovich K.J., Horowitz J.M., Friend S.H., Raybuck M., Weingberg R.A., and Harlow E. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (London) 334 (1988) 124-129
307. Williams R.S., Johnston S.A., Riedy M., DeVit J.M., McElligott S.G., and Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2726-2730
308. Woolf T.M. To cleave or not to cleave: Ribozymes and antisense. Antisense Res. Dev. 5 (1995) 227-232
309. Woolf T.M., and Budker V. Cationic lipid-mediated gene transfer. In: Sobol R.E., and Scanlon K.J. (Eds). The Internet Book of Gene Therapy: Cancer Therapeutics (1995), Appleton & Lange, Stamford, Connecticut. 65-73
310. Wright L., Wilson S.B., Milliken S., Biggs J., and Kearney P. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp. Hemortol. (N.Y.) 21 (1993) 1714-1718
311. Wu G.Y., and Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262 (1987) 4429-4432
312. Wu G.Y., and Wu C.H. Evidence for targeted gene delivery to hepG2 hepatoma cells in vitro. Biochemistry 27 (1988) 887-892
313. Wu G.Y., Zhan P., Sze L.L., Rosenberg A.R., and Wu C.H. Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. J. Biol. Chem. 269 (1994) 11542-11546
314. Wu H.-N., and Lai M.M.C. RNA conformational requirements of self-cleavage of hepatitis delta virus RNA. Mol. Cell. Biol. 10 (1990) 5575-5579
315. Wu H.-N., Lin Y.-J., Lin F.-P., Makino S., Chang M.-F., and Lai M.M.C. Human hepatitis δ virus RNA subfragments contain an autocleavage activity. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 1831-1835
316. Wurm F.M., Gwinn K.A., and Kingston R.E. Inducible overproduction of the mouse c-myc protein in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 5414
317. Yang J.H., Perreault J.-P., Labuda D., Usman N., and Cedergren R. Mixed DNA/RNA polymers are cleaved by the hammerhead ribozyme. Biochemistry 29 (1990) 11156-11160
318. Yang J.H., Usman N., Chartrand P., and Cedergren R. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry 31 (1992) 5005-5009
319. Yang N.-S., Burkholder J., Roberts B., Martinell B., and McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2726-2730
320. Yang Y., Ertle H.C., and Wilson J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1 (1994) 433-442
321. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gohezd E., and Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene expression. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4407-4411
322. Zenke M., Steinlein P., Wagner E., Cotten M., Beug H., and Birnstiel M.L. Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3655-3659
323. Zhang W.-W., Fujiwara T., Grimm E.A., and Roth J.A. Advances in cancer gene therapy. Adv. Pharmacol. 32 (1995) 289-341
324. Zhao J.J., and Pick L. Generating loss-of-function phenorypes of the gene with targeted ribozyme in Drosophila. fushi tarazu. Nature (London) 365 (1993) 448-451
325. Zhou S.Z., Broxmeyer H.E., Cooper S., Harrington M.A., and Srivastara A. Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp. Hematol. (N.Y.) 21 (1993) 928-933
326. Zhu N., Liggit D., Liu Y., and Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261 (1993) 209-211